Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Faron Pharmaceuticals OY (FARN) NPV

Sell:420.00p Buy:460.00p 0 Change: 15.00p (3.53%)
Market closed Prices as at close on 18 September 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:420.00p
Buy:460.00p
Change: 15.00p (3.53%)
Market closed Prices as at close on 18 September 2020 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:420.00p
Buy:460.00p
Change: 15.00p (3.53%)
Market closed Prices as at close on 18 September 2020 Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Faron Pharmaceuticals Oy is a Finland-based clinical stage biopharmaceutical company. The Company’s pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The Company has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic condition. It is undergoing Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) and European Phase II trial for the prevention of multi-organ failure after emergency aortic surgery for a Rupture of Abdominal Aorta Aneurysm (RAAA). Clevegen is a ground breaking early clinical anti-Clever-1 antibody able to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. It may be used alone or in combination with other immune checkpoint molecules.

Contact details

Address:
Joukahaisenkatu 6
TURKU
20520
Finland
Telephone:
+358 (02) 4695151
Website:
https://www.faron.com/

Important dates

Future events
Interim results 24 September 2020 24/09/20
Past events
AGM 18 May 2020 18/05/20
AGM 15 April 2020 15/04/20
Annual report 25 March 2020 25/03/20
Final results 20 March 2020 20/03/20
EGM 25 October 2019 25/10/19
Interim results 23 September 2019 23/09/19

General stock information

EPIC:
FARN
ISIN:
FI4000153309
Market cap:
£205.92 million
Shares in issue:
46.80 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Markku Jalkanen
    Chief Executive Officer, Founder, Member of the Executive Board
  • Yrjo Wichmann
    Chief Financial Officer, Member of the Executive Board
  • Mikael Maksimow
    Vice President Operations
  • Ilse Piippo
    Vice President Drug Development, Chief Medical Officer
  • Matti Karvonen
    Medical Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.